Samsung Bioepis Flags Shifts in US Biosimilar Market with Q1 2026 Report
Event summary
- 90 biosimilars approved in the US as of December 2025, with 63 (70%) launched.
- Average ASPs decreased by 52% within five years of first biosimilar launch, up to 77% in mature markets.
- Four aflibercept biosimilars await clearance, currently facing one competitor with a 12% WAC discount.
- Q1 2026 report highlights evolving PBM rebate contract models and their potential impact on biosimilar market dynamics.
The big picture
Samsung Bioepis' Q1 2026 report underscores the ongoing transformation of US drug pricing models, particularly through Pharmacy Benefit Manager (PBM) rebate structures. The shift toward alternative pricing reimbursement and transparency reflects broader industry efforts to manage rising healthcare costs while balancing biosimilar adoption. With 90 approved biosimilars now in the market, the report highlights both the competitive pressures and pricing efficiencies reshaping the biopharmaceutical landscape.
What we're watching
- PBM Contracting Shifts
- How evolving PBM rebate frameworks will influence biosimilar utilization patterns and market competition.
- Price Reduction Trends
- Whether the observed ASP declines can be sustained across all molecules, given intentional repositioning and product removals.
- Market Entry Dynamics
- The pace at which pending biosimilar launches (e.g., aflibercept) will intensify price competition in specific therapeutic areas.
Related topics